BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26385482)

  • 1. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
    Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
    J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
    Chen P; Li J; Jiang HG; Lan T; Chen YC
    Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.
    Li Y; Zhao L; Sun H; Yu J; Li N; Liang J; Wang Y; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
    PLoS One; 2012; 7(8):e44254. PubMed ID: 22952942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
    He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
    Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
    Yao C; Du W; Chen H; Xiao S; Huang L; Chen F
    Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
    Snyder ER; Ricker JL; Chen Z; Waes CV
    Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.
    Yao C; Du W; Chen H; Xiao S; Huang L; Chen FP
    Mol Med Rep; 2015 Jun; 11(6):4605-10. PubMed ID: 25647473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
    Burkitt K; Ljungman M
    Mol Cancer; 2008 Mar; 7():24. PubMed ID: 18325101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNAi-mediated knockdown of FANCF suppresses cell proliferation, migration, invasion, and drug resistance potential of breast cancer cells.
    Zhao L; Li N; Yu JK; Tang HT; Li YL; He M; Yu ZJ; Bai XF; Zheng ZH; Wang EH; Wei MJ
    Braz J Med Biol Res; 2014 Jan; 47(1):24-34. PubMed ID: 24345874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
    Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
    Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Fanconi anemia pathway sensitizes to DNA alkylating agents by inducing JNK-p53-dependent mitochondrial apoptosis in breast cancer cells.
    Zhao L; Li Y; He M; Song Z; Lin S; Yu Z; Bai X; Wang E; Wei M
    Int J Oncol; 2014 Jul; 45(1):129-38. PubMed ID: 24789349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
    Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
    Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
    Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
    Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells.
    Zhang J; Wang X; Lin CJ; Couch FJ; Fei P
    Cancer Biol Ther; 2006 Dec; 5(12):1632-6. PubMed ID: 17106252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.
    D'Andrea AD
    Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
    Nakashima S; Kobayashi S; Nagano H; Tomokuni A; Tomimaru Y; Asaoka T; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
    Cancer Sci; 2015 May; 106(5):584-91. PubMed ID: 25736055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
    Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
    Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drosophila homologs of FANCD2 and FANCL function in DNA repair.
    Marek LR; Bale AE
    DNA Repair (Amst); 2006 Nov; 5(11):1317-26. PubMed ID: 16860002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network.
    Geng L; Huntoon CJ; Karnitz LM
    J Cell Biol; 2010 Oct; 191(2):249-57. PubMed ID: 20937699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.